antigenics inc antigenics inc said data from a late stage trial for its kidney cancer treatment showed patients had less disease recurrence and improved overall survival the new york drug developers share price rose cents or to &# as of p m in nasdaq stock market composite trading the treatment a therapeutic vaccine called oncophage demonstrated "clinically significant improvement" in about of patients with intermediate risk for disease recurrence in a phase iii trial subset the company said currently there arent any approved therapies for such patients whose numbers are growing because of the increased use of early detection techniques said christopher wood an associate professor of urology at m d anderson cancer center in houston 
